Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by investment analysts at WBB Securities in a note issued to investors on Monday. They currently have a $75.00 target price on the biopharmaceutical company’s stock.
OMER has been the subject of a number of other research reports. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, October 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price target on shares of Omeros Corporation in a report on Wednesday, August 10th. FBR & Co reissued an “outperform” rating and issued a $38.00 price target on shares of Omeros Corporation in a report on Wednesday, June 29th. Maxim Group reissued a “buy” rating and issued a $30.00 price target on shares of Omeros Corporation in a report on Thursday, July 28th. Finally, S&P Equity Research boosted their price target on Omeros Corporation from $7.65 to $8.63 in a report on Monday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $32.45.
Omeros Corporation (NASDAQ:OMER) opened at 7.50 on Monday. The company’s market capitalization is $294.70 million. Omeros Corporation has a 52-week low of $7.20 and a 52-week high of $16.80. The stock’s 50 day moving average price is $10.41 and its 200-day moving average price is $11.57.
Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.18. The firm had revenue of $10 million for the quarter, compared to analyst estimates of $9.80 million. During the same period last year, the firm earned ($0.44) EPS. The company’s revenue for the quarter was up 212.5% compared to the same quarter last year. Analysts predict that Omeros Corporation will post ($1.55) earnings per share for the current fiscal year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the sale, the vice president now directly owns 179,597 shares in the company, valued at $1,959,403.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the completion of the sale, the vice president now owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of OMER. Ingalls & Snyder LLC acquired a new stake in Omeros Corporation during the second quarter worth approximately $46,441,000. Bank of Montreal Can acquired a new stake in Omeros Corporation during the second quarter worth approximately $17,641,000. BlackRock Fund Advisors boosted its stake in Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock worth $22,580,000 after buying an additional 10,605 shares during the period. Vanguard Group Inc. boosted its stake in Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock worth $15,045,000 after buying an additional 32,401 shares during the period. Finally, State Street Corp boosted its stake in Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock worth $9,274,000 after buying an additional 126,595 shares during the period. Institutional investors and hedge funds own 48.04% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.